Betrixaban, an oral factor Xa inhibitor, was compared to warfarin in patients with non-valvular atrial fibrillation with an additional risk factor for stroke in the Randomized Clinical trial of Three Doses of a Long-acting Oral direct Factor Xa Inhibitor Betrixaban in Patients With Atrial fibrillation (EXPLORE-Xa) trial [38,42,43]. The gene discussed is F10; the disease is stroke disorder.